Vanda Pharmaceuticals (VNDA) Net Margin (2010 - 2026)

Vanda Pharmaceuticals has reported Net Margin for 17 years, with the latest figure at 93.82% in Q1 2026.

• Quarterly Net Margin fell 3488.0% year-over-year to 93.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 109.97% (down 8800.0% YoY) and the FY2025 annual result came in at 102.02%, down 9251.0% from the prior year.
• Net Margin advanced to 93.82% in Q1 2026 per VNDA's latest filing, from 246.76% in the prior quarter.
• Over five years, Net Margin peaked at 10.64% in Q4 2022 and troughed at 246.76% in Q4 2025.
• A 5-year average of 30.41% and a median of 8.95% in 2024 frame the typical range for Net Margin.
• The sharpest annual moves came in 2023 and 2025: Net Margin jumped 1590 bps in 2023, then slumped 23759 bps in 2025.
• Over 5 years, Net Margin stood at 10.64% in 2022, then tumbled by 150 bps to 5.28% in 2023, then plunged by 74 bps to 9.17% in 2024, then slumped by 2592 bps to 246.76% in 2025, then jumped by 62 bps to 93.82% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 93.82%, 246.76%, and 40.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.